Status:
TERMINATED
Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)
Lead Sponsor:
Eyetech Pharmaceuticals
Collaborating Sponsors:
Pfizer
Conditions:
Age-Related Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
PHASE4
Brief Summary
The purpose of the trial is to compare whether Macugen (pegaptanib sodium) in combination with PDT with Visudyne (verteporfin) is safe and effective in slowing down the leakage of fluid within the eye...
Eligibility Criteria
Inclusion
- Subjects of either gender; aged 50 years or greater.
- Subfoveal choroidal neovascularization (CNV) due to AMD with predominantly classic lesion composition
- Best corrected visual acuity in the study eye between 20/40 and 20/200
Exclusion
- Any prior PDT with Visudyne to the study eye
- Any previous AMD thermal laser therapy to the study eye
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
End Date :
October 1 2008
Estimated Enrollment :
360 Patients enrolled
Trial Details
Trial ID
NCT00134667
Start Date
March 1 2005
End Date
October 1 2008
Last Update
January 15 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Retina Centers, P.C., Northwest Location
Tucson, Arizona, United States, 85704-5614